{
    "clinical_study": {
        "@rank": "72442", 
        "brief_summary": {
            "textblock": "RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing\n      so they stop growing or die.\n\n      PURPOSE: Phase II trial to study the effectiveness of gemcitabine in treating patients who\n      have advanced colorectal cancer."
        }, 
        "brief_title": "Gemcitabine in Treating Patients With Advanced Colorectal Cancer", 
        "condition": "Colorectal Cancer", 
        "condition_browse": {
            "mesh_term": "Colorectal Neoplasms"
        }, 
        "detailed_description": {
            "textblock": "OBJECTIVES:\n\n        -  Determine the response rate in patients with advanced colorectal cancer treated with\n           gemcitabine.\n\n        -  Determine the toxic effects of this drug in these patients.\n\n        -  Determine the progression-free survival of patients treated with this drug.\n\n      OUTLINE: This is a multicenter study.\n\n      Patients receive gemcitabine IV continuously over 24 hours on days 1, 8, and 15. Treatment\n      repeats every 28 days for a total of 6 courses in the absence of disease progression or\n      unacceptable toxicity.\n\n      Patients are followed every 6 months.\n\n      PROJECTED ACCRUAL: A total of 12-41 patients will be accrued for this study within 2 years."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "DISEASE CHARACTERISTICS: Histologically confirmed advanced colorectal cancer that has\n        failed at least 1\n\n        prior course of fluoropyrimidine-based chemotherapy\n\n        Measurable and/or evaluable disease\n\n        PATIENT CHARACTERISTICS:\n\n        Age:\n\n          -  18 and over\n\n        Performance status:\n\n          -  0-2\n\n        Life expectancy:\n\n          -  At least 3 months\n\n        Hematopoietic:\n\n          -  WBC at least 3,000/mm3\n\n          -  Platelet count at least 100,000/mm3\n\n        Hepatic:\n\n          -  Bilirubin no greater than 2.5 times upper limit of normal (ULN)\n\n          -  ALT and/or AST no greater than 3 times ULN (no greater than 10 times ULN if\n\n          -  secondary to hepatic involvement by tumor\n\n        Renal:\n\n          -  Creatinine no greater than 2.0 mg/dL\n\n        Cardiovascular:\n\n          -  No history of cardiac arrhythmias requiring chronic treatment beyond an\n\n          -  acute event (e.g., arrhythmias during severe electrolyte abnormalities\n\n          -  allowed)\n\n          -  No active cardiac disease requiring treatment other than hypertension,\n\n          -  stable angina, or chronic valvular disease\n\n        Other:\n\n          -  No other malignancy within the past 5 years except curatively treated\n\n          -  (including surgically cured) cancer\n\n          -  No serious medical or psychiatric illness that would preclude study\n\n          -  No active uncontrolled bacterial, fungal, or viral infection\n\n          -  Not pregnant or nursing\n\n          -  Negative pregnancy test\n\n          -  Fertile patients must use effective contraception\n\n        PRIOR CONCURRENT THERAPY:\n\n        Biologic therapy:\n\n          -  Not specified\n\n        Chemotherapy:\n\n          -  See Disease Characteristics\n\n          -  No more than 3 prior chemotherapy regimens\n\n          -  Must have 1 prior fluorouracil-based regimen and 1 other cytotoxic agent\n\n          -  (e.g., irinotecan)\n\n          -  More than 4 weeks since prior chemotherapy\n\n          -  Prior gemcitabine allowed\n\n          -  No other concurrent antineoplastic therapy\n\n        Endocrine therapy:\n\n          -  Not specified\n\n        Radiotherapy:\n\n          -  More than 4 weeks since prior radiotherapy\n\n        Surgery:\n\n          -  More than 4 weeks since prior surgery"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "firstreceived_date": "January 6, 2001", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00007943", 
            "org_study_id": "CDR0000068355", 
            "secondary_id": [
                "CCCWFU-59198", 
                "NCI-914"
            ]
        }, 
        "intervention": {
            "intervention_name": "gemcitabine hydrochloride", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": "Gemcitabine"
        }, 
        "keyword": [
            "stage III colon cancer", 
            "stage IV colon cancer", 
            "stage III rectal cancer", 
            "stage IV rectal cancer", 
            "recurrent colon cancer", 
            "recurrent rectal cancer"
        ], 
        "lastchanged_date": "August 20, 2009", 
        "link": {
            "description": "Clinical trial summary from the National Cancer Institute's PDQ\u00ae database", 
            "url": "http://cancer.gov/clinicaltrials/CCCWFU-59198"
        }, 
        "location": {
            "facility": {
                "address": {
                    "city": "Winston-Salem", 
                    "country": "United States", 
                    "state": "North Carolina", 
                    "zip": "27157-1082"
                }, 
                "name": "Comprehensive Cancer Center of Wake Forest University Baptist Medical Center"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "official_title": "A Phase II Study Of Twenty-Four Hour Infusion Gemcitabine For Advanced Colorectal Cancer", 
        "overall_official": {
            "affiliation": "Comprehensive Cancer Center of Wake Forest University", 
            "last_name": "Paul D. Savage, MD", 
            "role": "Study Chair"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Federal Government"
        }, 
        "phase": "Phase 2", 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00007943"
        }, 
        "source": "Wake Forest Baptist Health", 
        "sponsors": {
            "collaborator": {
                "agency": "National Cancer Institute (NCI)", 
                "agency_class": "NIH"
            }, 
            "lead_sponsor": {
                "agency": "Wake Forest Baptist Health", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "September 2000", 
        "study_design": "Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "August 2009"
    }, 
    "geocoordinates": {
        "Comprehensive Cancer Center of Wake Forest University Baptist Medical Center": "36.1 -80.244"
    }
}